Clinical trial
Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia
NCT00283179 · Taiwan Otsuka Pharm. Co., Ltd, Industry · Completed
Key facts
| NCT number | NCT00283179 |
|---|---|
| Title | Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia |
| Official title | Efficacy and Safety of Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia or Schizoaffective Disorder With Risperidone as an Active Control |
| Lead sponsor | Taiwan Otsuka Pharm. Co., Ltd, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia, Schizoaffective Disorder |
| Intervention type | Drug |
| Interventions | Aripiprazole, Risperidone |
| Enrollment | 83 |
| Start date | Mar 1, 2004 |
| Completion | Dec 1, 2004 |
| First posted | Jan 27, 2006 |
| Last update posted | May 15, 2008 |
| Countries | Taiwan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: